These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 34031671

  • 1. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
    Harringer S, Hejl M, Enyedy ÉA, Jakupec MA, Galanski MS, Keppler BK, Dyson PJ, Varbanov HP.
    Dalton Trans; 2021 Jun 21; 50(23):8167-8178. PubMed ID: 34031671
    [Abstract] [Full Text] [Related]

  • 2. Novel tetracarboxylatoplatinum(IV) complexes as carboplatin prodrugs.
    Varbanov HP, Valiahdi SM, Kowol CR, Jakupec MA, Galanski MS, Keppler BK.
    Dalton Trans; 2012 Dec 21; 41(47):14404-14415. PubMed ID: 22886297
    [Abstract] [Full Text] [Related]

  • 3. Optimization of axial ligands to promote the photoactivation of BODIPY-conjugated platinum(IV) anticancer prodrugs.
    Yao H, Gunawan YF, Liu G, Tse MK, Zhu G.
    Dalton Trans; 2021 Oct 12; 50(39):13737-13747. PubMed ID: 34519297
    [Abstract] [Full Text] [Related]

  • 4. Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivo.
    Ma ZY, Wang DB, Song XQ, Wu YG, Chen Q, Zhao CL, Li JY, Cheng SH, Xu JY.
    Eur J Med Chem; 2018 Sep 05; 157():1292-1299. PubMed ID: 30195239
    [Abstract] [Full Text] [Related]

  • 5. Tetracarboxylatoplatinum(IV) complexes featuring monodentate leaving groups - A rational approach toward exploiting the platinum(IV) prodrug strategy.
    Höfer D, Varbanov HP, Legin A, Jakupec MA, Roller A, Galanski MS, Keppler BK.
    J Inorg Biochem; 2015 Dec 05; 153():259-271. PubMed ID: 26365319
    [Abstract] [Full Text] [Related]

  • 6. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
    Yao H, Chen S, Deng Z, Tse MK, Matsuda Y, Zhu G.
    Inorg Chem; 2020 Aug 17; 59(16):11823-11833. PubMed ID: 32799491
    [Abstract] [Full Text] [Related]

  • 7. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
    Tan MX, Wang ZF, Qin QP, Zou BQ, Liang H.
    Dalton Trans; 2020 Feb 07; 49(5):1613-1619. PubMed ID: 31942585
    [Abstract] [Full Text] [Related]

  • 8. Nitric oxide-releasing platinum(IV) prodrug efficiently inhibits proliferation and metastasis of cancer cells.
    Dai Y, Zhu Y, Cheng J, Shen J, Huang H, Liu M, Chen Z, Liu Y.
    Chem Commun (Camb); 2020 Nov 12; 56(90):14051-14054. PubMed ID: 33103676
    [Abstract] [Full Text] [Related]

  • 9. Coordination-driven self-assembly of a Pt(iv) prodrug-conjugated supramolecular hexagon.
    Yue Z, Wang H, Li Y, Qin Y, Xu L, Bowers DJ, Gangoda M, Li X, Yang HB, Zheng YR.
    Chem Commun (Camb); 2018 Jan 18; 54(7):731-734. PubMed ID: 29303526
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Bis- and Tetrakis(carboxylato)platinum(IV) complexes with mixed axial ligands - synthesis, characterization, and cytotoxicity.
    Hoffmeister BR, Hejl M, Adib-Razavi MS, Jakupec MA, Galanski M, Keppler BK.
    Chem Biodivers; 2015 Apr 18; 12(4):559-74. PubMed ID: 25879501
    [Abstract] [Full Text] [Related]

  • 12. Alternative mechanism of action of the DNP PtIV prodrug: intracellular cisplatin release and the mitochondria-mediated apoptotic pathway.
    Krasnovskaya O, Spector D, Erofeev A, Gorelkin P, Akasov R, Skvortsov D, Trigub A, Vlasova K, Semkina A, Zyk N, Beloglazkina E, Majouga A.
    Dalton Trans; 2021 Jun 15; 50(23):7922-7927. PubMed ID: 34037020
    [Abstract] [Full Text] [Related]

  • 13. Are Pt(IV) Prodrugs That Release Combretastatin A4 True Multi-action Prodrugs?
    Schmidt C, Babu T, Kostrhunova H, Timm A, Basu U, Ott I, Gandin V, Brabec V, Gibson D.
    J Med Chem; 2021 Aug 12; 64(15):11364-11378. PubMed ID: 34342437
    [Abstract] [Full Text] [Related]

  • 14. A novel class of bis- and tris-chelate diam(m)inebis(dicarboxylato)platinum(IV) complexes as potential anticancer prodrugs.
    Varbanov HP, Göschl S, Heffeter P, Theiner S, Roller A, Jensen F, Jakupec MA, Berger W, Galanski MS, Keppler BK.
    J Med Chem; 2014 Aug 14; 57(15):6751-64. PubMed ID: 25032896
    [Abstract] [Full Text] [Related]

  • 15. Fluorogenic platinum(IV) complexes as potential predictors for the design of hypoxia-activated platinum(IV) prodrugs.
    Marsh JW, Hacker L, Huang S, Boulet MHC, White JRG, Martin LAW, Yeomans MA, Han HH, Diez-Perez I, Musgrave RA, Hammond EM, Sedgwick AC.
    Dalton Trans; 2024 Sep 10; 53(35):14811-14816. PubMed ID: 39169877
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pt(IV) Anticancer Prodrugs - A Tale of Mice and Men.
    Gibson D.
    ChemMedChem; 2021 Jul 20; 16(14):2188-2191. PubMed ID: 33928760
    [Abstract] [Full Text] [Related]

  • 18. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
    Xiao H, Yan L, Zhang Y, Qi R, Li W, Wang R, Liu S, Huang Y, Li Y, Jing X.
    Chem Commun (Camb); 2012 Nov 11; 48(87):10730-2. PubMed ID: 23012698
    [Abstract] [Full Text] [Related]

  • 19. Mono- and di-bromo platinum(IV) prodrugs via oxidative bromination: synthesis, characterization, and cytotoxicity.
    Xu Z, Wang Z, Yiu SM, Zhu G.
    Dalton Trans; 2015 Dec 14; 44(46):19918-26. PubMed ID: 26514681
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.